弥漫性浸润性大脑胶质瘤病表型的基因组决定因素
本研究回顾性分析2013至2023年影像学证实的63例大脑胶质瘤病(GC)患者(45例GBM-GC、18例IDH突变型星形细胞瘤-GC)及126例匹配对照,评估遗传改变与生存。GBM-GC中TERT启动子突变频率显著低于GBM匹配对照(38%对68%,p=0.002,FDR=0.04),IDH突变型星形细胞瘤-GC的无进展生存期短于匹配对照(p=0.036),但两组总生存期与对照均无显著差异。
要点
- GBM-GC的TERT启动子突变频率低于非GC的GBM对照。
- IDH突变型星形细胞瘤-GC的无进展生存期短于匹配对照。
- GBM-GC与IDH突变型星形细胞瘤-GC的总生存期与对照无显著差异。
核心结论
- GBM-GC中较低的TERT启动子突变频率可能是原发性GBM-GC的特征。
- GC患者的总生存期与匹配的非GC对照相似。
- 鉴于样本量小且为回顾性研究,结果需进一步研究验证。
研究设计与样本
- 回顾性研究,纳入2013至2023年影像学证实的GC病例63例(45例GBM-GC、18例IDH突变型星形细胞瘤-GC)及126例匹配对照。
- 评估遗传改变及总生存期(OS)与无进展生存期(PFS)。
主要发现
- GBM匹配对照中TERT启动子改变占68%,GBM-GC患者仅占38%(p=0.002,FDR=0.04)。
- 原发性GBM-GC亚组同样成立(p=0.002,FDR=0.04),继发性GBM-GC则不成立。
- GBM-GC与匹配对照的PFS无显著差异(p=0.720)。
- IDH突变型星形细胞瘤-GC的PFS短于匹配对照(p=0.036)。
- GBM-GC与IDH突变型星形细胞瘤-GC的OS与对照均无显著差异(p=0.589和p=0.39)。
关键数值与推荐
- GC定义为累及至少三个连续脑叶的弥漫性浸润性生长模式。
- 上述各组中没有任何遗传改变与PFS或OS显著相关。
临床怎么用
- 提示GBM-GC的分子特征可能与普通GBM不同,TERT启动子状态或有助于区分原发性GBM-GC。
- GC患者生存与匹配非GC对照相似,支持将GC患者纳入更多临床试验以完善分子特征认识。
局限性
- 样本量小。
- 回顾性研究设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Gliomatosis cerebri (GC) is defined as a diffusely infiltrative pattern of growth affecting at least three contiguous lobes of the brain. GC presents unique challenges in terms of surgery and radiation therapy. We evaluated the genomic determinants of GC. METHODS: In this retrospective study, we evaluated genetic alterations and overall (OS) and progression-free survival (PFS) durations in radiographically verified cases of GC (glioblastoma [GBM]-GC or astrocytoma IDH mutant-GC) from 2013 to 2023 and their matched non-GC controls. RESULTS: We identified 63 GC cases (45 GBM-GC and 18 astrocytoma IDH mutant-GC) and 126 matched controls. Statistically significant alterations in telomerase reverse transcriptase (TERT) promoter were found in 68% of the GBM matched controls versus only 38% of the GBM-GC patients (p = 0.002 and false discovery rate (FDR) = 0.04). The same held true for the subgroup of primary GBM-GC (p = 0.002 and FDR = 0.04) but not for secondary GBM-GC. In terms of PFS duration, the GBM-GC patients did not significantly differ from the matched controls (p = 0.720). However, the astrocytoma IDH mutant-GC patients had a shorter PFS duration than did the matched controls (p = 0.036). In terms of OS duration, neither the GBM-GC group nor the astrocytoma, IDH mutant-GC group significantly differed (p = 0.589 and p = 0.39, respectively). None of the genetic alterations in these groups were significantly associated with PFS or OS duration. CONCLUSIONS: The lower frequency of TERT promoter mutations in GBM-GC may be a characteristic of primary GBM-GC. GC patients had similar OS durations to those of matched non-GC controls. Further studies are needed to validate these results, given this study’s small sample size and retrospective nature. This study supports further efforts to understand the molecular characteristics of GC and perhaps include patients with GC in more clinical trials.
引用
- Dasgupta P, Dagher SA, Chi X, et al. Genomic determinants of the diffusely infiltrative gliomatosis cerebri phenotype. J Neurooncol. 2025. PMID: 41099968. doi:10.1007/s11060-025-05285-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。